BenzingaOctober 13, 2026 at 6:54 AM NY14 Days Ago
RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
